Developer docs
API playgroundTry for free, no card

Search company profiles

4D Medicine

Full company profile

uuid0004vdz

Namestring
4D Medicine
Legal namestring
4D Medicine Ltd
Company typeenum
Private
Founded yearint
2020
Descriptiontext

4D Medicine Ltd is a University of Birmingham and Warwick spin-out (founded April 2020) headquartered at MediCity Nottingham, UK, that develops and commercializes a patented photocurable polycarbonate-urethane polymer platform marketed as 4Degra® for use in bioabsorbable medical devices. The core technology addresses long-standing limitations of legacy resorbable polymers (PLA, PCL, PLGA) by eliminating acidic degradation by-products, enabling controlled surface (rather than bulk) erosion, providing tunable mechanical properties from soft/flexible to rigid, and offering shape-memory behavior suitable for minimally invasive delivery. 4Degra is compatible with multiple additive manufacturing modalities — SLA, DLP and micro-scale PµSL — as well as casting and conversion into films, meshes and microspheres, validated through partnerships with Rapid Shape and Boston Micro Fabrication. Two granted US patents (US11649318, US12275186B2) protect the composition and tunable property space. The group operates two wholly-owned subsidiaries: 4D Biomaterials Ltd (resin manufacturing, ISO 13485 certified March 2025) and 4D Medical Devices Ltd (device development, lead product being a bioabsorbable interference screw currently in FDA 510(k) review with anticipated clearance in early 2026).

The company monetizes its platform through four streams: sale of 4Degra resin to medical device manufacturers and 3D printing partners, licensing of the polymer technology for incorporation into partner products, 4D Design services (requirements development, design optimization with degradation modeling, prototype testing and manufacturing transfer), and — once cleared — direct sales of proprietary bioabsorbable devices. Customers and end-users span musculoskeletal/orthopaedics (the lead focus), soft tissue regeneration (cardiovascular, breast, surgical meshes, women's and men's health), and drug delivery (localized elution of antibiotics, anti-proliferatives, growth factors, hormones). The commercial motion is enterprise-direct and partnership-led, supplemented by presence at industry events (Formnext, Med-Tech Expo, 3D Medtech Printing Conference) and targeted at medical device manufacturers, contract designers and channel partners across global geographies, with the US market as the principal near-term prize via FDA clearance.

Capitalization to date totals approximately £5m across pre-seed (£478k: Innovate UK grant + SFC Capital, 2020), seed (£1.6m led by DSW Ventures with MEIF/Mercia and SFC Capital, 2021) and Series A (£3.4m led by Oshen Holdings with DSW Ventures, SFC Capital and Boundary Capital, July 2024), plus subsequent smaller SFC Capital tranches disclosed in funding-round data. The leadership team has been deliberately upgraded for commercial scale-up: serial medtech operator Philip Smith (CEO, since spin-out), Professor Andrew Dove (Founder/CSO, the underlying researcher), Dr Andy Naylor (COO, promoted January 2024 from Head of R&D Operations), Tom Buckland (Chairman, June 2024 — track record including ApaTech/Baxter $330m exit), and Piers Morgan (CFO, 2024 — ~$800m of biotech financings led). The company is positioned at the pre-clearance commercial inflection point: ISO 13485 achieved, FDA 510(k) pending, with a Series B raise anticipated to fund US market entry.

Short descriptiontext

4D Medicine Ltd is a UK spin-out developing and commercializing 4Degra®, a patented photocurable polycarbonate-urethane polymer platform for bioabsorbable medical devices, selling resin, licensing technology and design services to medical device manufacturers across orthopaedic, soft tissue and drug delivery applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioresorbable polymers, bioabsorbable medical devices, photocurable resin platform, 3D printed implants, medical grade biomaterials
Industry4 codes
PRIMARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAEAOAL
Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
NAICS code4 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Resin and Synthetic Rubber Manufacturing32521
  • Medical Equipment and Supplies Manufacturing3391
  • Scientific Research and Development Services5417
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Plastic Materials, Synth Resins & Nonvulcan Elastomers2821
  • Surgical & Medical Instruments & Apparatus3841
Product category
Bioabsorbable Medical Devices and Biomaterials
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
14Degra Resin Product Sales
TypeHardware Sales
Description

Sale of proprietary 4Degra photocurable polycarbonate-urethane polymer resins to medical device manufacturers and partners. Revenue from direct product sales of material consumables for 3D printing applications.

4dmedicine.co.uk
2Medical Device Licensing
TypeLicensing Royalties
Description

Licensing agreements with medical device companies for use of 4Degra technology in their products. Multiple growth pathways including licensing agreements for global expansion.

4dmedicine.co.uk
34D Design Services
TypeProfessional Services
Description

Expert design and innovation services supporting medical device innovators developing 4Degra-based products. Services include product requirements development, design optimisation with degradation modeling, prototype performance testing, and manufacturing transfer support.

4dmedicine.co.uk
4Proprietary Medical Device Sales
TypeOne Time License
Description

Direct sales of proprietary bioabsorbable medical devices developed internally. First product (bioabsorbable interference screw) targeting FDA clearance in early 2026 for musculoskeletal market entry.

4dmedicine.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
14Degra
Description

Proprietary photocurable polycarbonate urethane polymer platform for bioabsorbable medical devices. Can be processed via 3D printing, casting, or conversion into films and meshes. Used in musculoskeletal, soft tissue, and drug delivery applications.

4dmedicine.co.uk
+1 more record
Core offering1 text field

4D Medicine develops and commercialises 4Degra®, a patented photocurable polycarbonate-urethane polymer platform sold as resin to medical device manufacturers for 3D-printed bioabsorbable implants. The company also licenses its chemistry to device makers and provides 4D Design™ expert design services for developing 4Degra-based products, while internally developing proprietary bioabsorbable medical devices led by a bioabsorbable interference screw for musculoskeletal soft tissue fixation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Controlled surface degradation vs bulk erosion - prevents rapid structural loss and acidic by-products
+2 more records
Product and service3 records
14Degra® Photocurable Polycarbonate-Urethane Resin Platform
CategoryBioabsorbable Biomaterials
24D Design™ Expert Design and Innovation Services
CategoryMedical Device Design Services
3Bioabsorbable Interference Screw
CategoryBioabsorbable Medical Devices
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2021-12-07
Description

Partnership enabling micro-scale 3D printing using 4Degra bioresorbable materials. First time bioresorbable material printed using micro 3D printing technology. Opens micro-scale medical device applications.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2021-11-16
Description

Partnership to evaluate medical device applications with new bioresorbable 3D printing resins using next generation vat polymerization technology. Rapid Shape's DLP machines matched with 4Degra resin inks for medical device development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-10
Description

Spin-out origin. Research conducted in Professor Andrew Dove's group. Patents filed by university now licensed to 4D Medicine.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-10
Description

Spin-out origin. Original research location of Professor Dove's group before relocation to Birmingham.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

BoneSupport is a Swedish orthobiologics company commercialising bioabsorbable ceramic bone graft substitutes — an emerging player with overlapping musculoskeletal end-market focus and a comparable regulatory/commercialisation trajectory for bioabsorbable medical devices.

TypeBroad incumbent
Description

Stryker is a global orthopaedic and medical device leader with an installed base that includes bioabsorbable fixation products — a broad incumbent whose orthopaedic franchise directly competes with 4D Medicine's lead interference screw category, while also representing a potential OEM licensing partner.

TypeBroad incumbent
Description

Smith+Nephew operates a global orthopaedics and sports medicine portfolio that includes bioabsorbable fixation technologies — a broad incumbent competing in the same end markets (sports medicine soft-tissue repair, orthopaedic fixation) targeted by 4D Medicine's lead product.

TypeBroad incumbent
Description

DSM Biomedical (now operating as Covation Bio) supplies a broad portfolio of bioabsorbable and biostable materials to medical device and pharmaceutical companies — an established incumbent comparable to 4D Medicine's 4D Biomaterials subsidiary in customer base, regulatory depth, and product breadth, though at materially greater scale.

5TEPHA Inc.
TypeDirect peer
Description

TEPHA develops proprietary bioabsorbable polymers (including PHA-based materials) for medical implants and devices — a direct peer in the bioabsorbable polymer platform space, targeting similar orthopaedic, soft-tissue, and surgical device applications as 4D Medicine.

TypeDirect peer
Description

Bioretec is a Finnish medical device company developing bioabsorbable orthopaedic implants (bone screws, pins, plates) — directly comparable to 4D Medicine's lead product (bioabsorbable interference screw) and an early commercial-stage reference point for bioabsorbable orthopaedic device commercialisation.

TypeDirect peer
Description

Poly-Med develops and manufactures bioabsorbable polymers and resorbable medical devices, including fibres, meshes, and fixation devices — a focused direct competitor to 4D Medicine in both the materials platform and finished orthopaedic/surgical device categories.

TypeDirect peer
Description

Corbion's PURASORB portfolio is one of the leading bioabsorbable polymer lines (PLA, PLGA, PCL) used in medical implants and drug-delivery applications — directly comparable to 4Degra® in chemistry, end markets, and customer base of medical device manufacturers and pharmaceutical partners.

TypeEmerging player
Description

Sirakoss developed bioabsorbable bone graft substitute materials, was a University of Aberdeen spin-out, and was led to an $11m exit by 4D Medicine's current Chairman Tom Buckland — a closely related UK bioabsorbable medtech comparable in academic origin, regulatory pathway, and orthopaedic end-market focus.

TypeDirect peer
Description

Evonik's RESOMER line is the dominant commercial bioabsorbable PLA/PLGA polymer portfolio for medical devices and implants — the most direct competitive incumbent to 4D Medicine's 4Degra® platform, serving the same medical device OEMs with overlapping indications in orthopaedics, drug delivery, and tissue engineering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4D Medicine

Bioabsorbable Medical Devices and Biomaterials4dmedicine.co.uk

4D Medicine Ltd is a UK spin-out developing and commercializing 4Degra®, a patented photocurable polycarbonate-urethane polymer platform for bioabsorbable medical devices, selling resin, licensing technology and design services to medical device manufacturers across orthopaedic, soft tissue and drug delivery applications.

What 4D Medicine does

4D Medicine Ltd is a University of Birmingham and Warwick spin-out (founded April 2020) headquartered at MediCity Nottingham, UK, that develops and commercializes a patented photocurable polycarbonate-urethane polymer platform marketed as 4Degra® for use in bioabsorbable medical devices. The core technology addresses long-standing limitations of legacy resorbable polymers (PLA, PCL, PLGA) by eliminating acidic degradation by-products, enabling controlled surface (rather than bulk) erosion, providing tunable mechanical properties from soft/flexible to rigid, and offering shape-memory behavior suitable for minimally invasive delivery. 4Degra is compatible with multiple additive manufacturing modalities — SLA, DLP and micro-scale PµSL — as well as casting and conversion into films, meshes and microspheres, validated through partnerships with Rapid Shape and Boston Micro Fabrication. Two granted US patents (US11649318, US12275186B2) protect the composition and tunable property space. The group operates two wholly-owned subsidiaries: 4D Biomaterials Ltd (resin manufacturing, ISO 13485 certified March 2025) and 4D Medical Devices Ltd (device development, lead product being a bioabsorbable interference screw currently in FDA 510(k) review with anticipated clearance in early 2026).

The company monetizes its platform through four streams: sale of 4Degra resin to medical device manufacturers and 3D printing partners, licensing of the polymer technology for incorporation into partner products, 4D Design services (requirements development, design optimization with degradation modeling, prototype testing and manufacturing transfer), and — once cleared — direct sales of proprietary bioabsorbable devices. Customers and end-users span musculoskeletal/orthopaedics (the lead focus), soft tissue regeneration (cardiovascular, breast, surgical meshes, women's and men's health), and drug delivery (localized elution of antibiotics, anti-proliferatives, growth factors, hormones). The commercial motion is enterprise-direct and partnership-led, supplemented by presence at industry events (Formnext, Med-Tech Expo, 3D Medtech Printing Conference) and targeted at medical device manufacturers, contract designers and channel partners across global geographies, with the US market as the principal near-term prize via FDA clearance.

Capitalization to date totals approximately £5m across pre-seed (£478k: Innovate UK grant + SFC Capital, 2020), seed (£1.6m led by DSW Ventures with MEIF/Mercia and SFC Capital, 2021) and Series A (£3.4m led by Oshen Holdings with DSW Ventures, SFC Capital and Boundary Capital, July 2024), plus subsequent smaller SFC Capital tranches disclosed in funding-round data. The leadership team has been deliberately upgraded for commercial scale-up: serial medtech operator Philip Smith (CEO, since spin-out), Professor Andrew Dove (Founder/CSO, the underlying researcher), Dr Andy Naylor (COO, promoted January 2024 from Head of R&D Operations), Tom Buckland (Chairman, June 2024 — track record including ApaTech/Baxter $330m exit), and Piers Morgan (CFO, 2024 — ~$800m of biotech financings led). The company is positioned at the pre-clearance commercial inflection point: ISO 13485 achieved, FDA 510(k) pending, with a Series B raise anticipated to fund US market entry.

4D Medicine firmographics

Firmographics
Name
4D Medicine
Legal name
4D Medicine Ltd
Website
https://4dmedicine.co.uk
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
4D Medicine Ltd is a UK spin-out developing and commercializing 4Degra®, a patented photocurable polycarbonate-urethane polymer platform for bioabsorbable medical devices, selling resin, licensing technology and design services to medical device manufacturers across orthopaedic, soft tissue and drug delivery applications.
Ownership category
akta.pro rank

4D Medicine industry classification

Industry
Product category
Bioabsorbable Medical Devices and Biomaterials
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Resin and Synthetic Rubber Manufacturing (32521), Medical Equipment and Supplies Manufacturing (3391), Scientific Research and Development Services (5417)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAEAOAL
Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)

Keywords

  • Bioresorbable polymers
  • Bioabsorbable medical devices
  • Photocurable resin platform
  • 3D printed implants
  • Medical grade biomaterials

Where 4D Medicine is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

4D Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. 4Degra Resin Product Sales: Sale of proprietary 4Degra photocurable polycarbonate-urethane polymer resins to medical device manufacturers and partners. Revenue from direct product sales of material consumables for 3D printing applications.
  2. Medical Device Licensing: Licensing agreements with medical device companies for use of 4Degra technology in their products. Multiple growth pathways including licensing agreements for global expansion.
  3. 4D Design Services: Expert design and innovation services supporting medical device innovators developing 4Degra-based products. Services include product requirements development, design optimisation with degradation modeling, prototype performance testing, and manufacturing transfer support.
  4. Proprietary Medical Device Sales: Direct sales of proprietary bioabsorbable medical devices developed internally. First product (bioabsorbable interference screw) targeting FDA clearance in early 2026 for musculoskeletal market entry.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

4D Medicine product offering

Product offering

Core offering

4D Medicine develops and commercialises 4Degra®, a patented photocurable polycarbonate-urethane polymer platform sold as resin to medical device manufacturers for 3D-printed bioabsorbable implants. The company also licenses its chemistry to device makers and provides 4D Design™ expert design services for developing 4Degra-based products, while internally developing proprietary bioabsorbable medical devices led by a bioabsorbable interference screw for musculoskeletal soft tissue fixation.

Differentiator

Problem solved

Functional benefit

Brands

  • 4Degra: Proprietary photocurable polycarbonate urethane polymer platform for bioabsorbable medical devices. Can be processed via 3D printing, casting, or conversion into films and meshes. Used in musculoskeletal, soft tissue, and drug delivery applications.
  • 4D Design

Products and services

  • 4Degra® Photocurable Polycarbonate-Urethane Resin Platform
  • 4D Design™ Expert Design and Innovation Services
  • Bioabsorbable Interference Screw

Quantifiable outcome

  • Controlled surface degradation vs bulk erosion - prevents rapid structural loss and acidic by-products
  • +2 more outcomes

Companies that use 4D Medicine

Customer profile

Segments4 records

Ideal customer profiles2 records

4D Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

4D Medicine partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic and core.

  • Boston Micro Fabrication (BMF)strategicTechnology or Integration · 7 December 2021Partnership enabling micro-scale 3D printing using 4Degra bioresorbable materials. First time bioresorbable material printed using micro 3D printing technology. Opens micro-scale medical device applications.
  • Rapid ShapestrategicTechnology or Integration · 16 November 2021Partnership to evaluate medical device applications with new bioresorbable 3D printing resins using next generation vat polymerization technology. Rapid Shape's DLP machines matched with 4Degra resin inks for medical device development.
  • University of BirminghamcoreStrategic or Co-development Partner · 10 July 2020Spin-out origin. Research conducted in Professor Andrew Dove's group. Patents filed by university now licensed to 4D Medicine.
  • University of WarwickcoreStrategic or Co-development Partner · 10 July 2020Spin-out origin. Original research location of Professor Dove's group before relocation to Birmingham.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

4D Medicine competitors and assessment

Company assessment

Emerging players

  • BoneSupport: BoneSupport is a Swedish orthobiologics company commercialising bioabsorbable ceramic bone graft substitutes — an emerging player with overlapping musculoskeletal end-market focus and a comparable regulatory/commercialisation trajectory for bioabsorbable medical devices.
  • Sirakoss: Sirakoss developed bioabsorbable bone graft substitute materials, was a University of Aberdeen spin-out, and was led to an $11m exit by 4D Medicine's current Chairman Tom Buckland — a closely related UK bioabsorbable medtech comparable in academic origin, regulatory pathway, and orthopaedic end-market focus.

Broad incumbents

  • Stryker: Stryker is a global orthopaedic and medical device leader with an installed base that includes bioabsorbable fixation products — a broad incumbent whose orthopaedic franchise directly competes with 4D Medicine's lead interference screw category, while also representing a potential OEM licensing partner.
  • Smith+Nephew: Smith+Nephew operates a global orthopaedics and sports medicine portfolio that includes bioabsorbable fixation technologies — a broad incumbent competing in the same end markets (sports medicine soft-tissue repair, orthopaedic fixation) targeted by 4D Medicine's lead product.
  • DSM Biomedical (Covation Bio): DSM Biomedical (now operating as Covation Bio) supplies a broad portfolio of bioabsorbable and biostable materials to medical device and pharmaceutical companies — an established incumbent comparable to 4D Medicine's 4D Biomaterials subsidiary in customer base, regulatory depth, and product breadth, though at materially greater scale.

Direct peers

  • TEPHA Inc. TEPHA develops proprietary bioabsorbable polymers (including PHA-based materials) for medical implants and devices — a direct peer in the bioabsorbable polymer platform space, targeting similar orthopaedic, soft-tissue, and surgical device applications as 4D Medicine.
  • Bioretec: Bioretec is a Finnish medical device company developing bioabsorbable orthopaedic implants (bone screws, pins, plates) — directly comparable to 4D Medicine's lead product (bioabsorbable interference screw) and an early commercial-stage reference point for bioabsorbable orthopaedic device commercialisation.
  • Poly-Med: Poly-Med develops and manufactures bioabsorbable polymers and resorbable medical devices, including fibres, meshes, and fixation devices — a focused direct competitor to 4D Medicine in both the materials platform and finished orthopaedic/surgical device categories.
  • Corbion (PURASORB): Corbion's PURASORB portfolio is one of the leading bioabsorbable polymer lines (PLA, PLGA, PCL) used in medical implants and drug-delivery applications — directly comparable to 4Degra® in chemistry, end markets, and customer base of medical device manufacturers and pharmaceutical partners.
  • Evonik (RESOMER): Evonik's RESOMER line is the dominant commercial bioabsorbable PLA/PLGA polymer portfolio for medical devices and implants — the most direct competitive incumbent to 4D Medicine's 4Degra® platform, serving the same medical device OEMs with overlapping indications in orthopaedics, drug delivery, and tissue engineering.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

4D Medicine social profiles

Digital presence

4D Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4D Medicine leadership team

Management profile

Number of profiles

Profiles8 records

4D Medicine subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

4D Medicine funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4D Medicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4D Medicine

What does 4D Medicine do?

4D Medicine develops and commercialises 4Degra®, a patented photocurable polycarbonate-urethane polymer platform sold as resin to medical device manufacturers for 3D-printed bioabsorbable implants. The company also licenses its chemistry to device makers and provides 4D Design™ expert design services for developing 4Degra-based products, while internally developing proprietary bioabsorbable medical devices led by a bioabsorbable interference screw for musculoskeletal soft tissue fixation.

Is 4D Medicine a public or private company?

4D Medicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was 4D Medicine founded?

4D Medicine was founded in 2020. It employs 11 to 50 people.

Where is 4D Medicine based?

4D Medicine is headquartered in Nottingham, United Kingdom, in the Europe region.

How does 4D Medicine make money?

Four revenue lines are on record. 4Degra Resin Product Sales are the primary driver. The others are medical Device Licensing, 4D Design Services and proprietary Medical Device Sales.

Who are 4D Medicine's main competitors?

Emerging players on record are BoneSupport and Sirakoss. Broad incumbents are Stryker, Smith+Nephew and DSM Biomedical (Covation Bio). Direct peers are TEPHA Inc., Bioretec, Poly-Med, Corbion (PURASORB) and Evonik (RESOMER).

Does 4D Medicine have an API?

No public API is recorded for 4D Medicine.

What industry is 4D Medicine in?

4D Medicine's product category is Bioabsorbable Medical Devices and Biomaterials. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaBiotech firm 4D Medicine Ltd names new non-executive chairmanNottingham-based medical device and biomaterials company 4D Medicine Ltd has appointed Andrew Newland as its new non-executive chairman, succeeding Dr Tom Buckland who stepped down after two and a half years of service. Newland brings extensive experience from his previous role as founder and CEO of specialty diagnostics company ANGLE plc, including US FDA product clearance and an IPO. The company is working toward securing FDA clearance for its first peripheral nerve protection products, preparing for a Series B financing round, and planning a US market launch.LinkedIn🚀 The SFC All-Star Fund EIS 2025/2026 I is now closed! We are thrilled to announce the successful deployment of our latest EIS fund. For this cohort, our investment team selected 10 of the…SFC has announced the successful closing and deployment of its SFC All-Star Fund EIS 2025/2026 I, backing 10 companies previously supported at the SEIS stage. The fund selected British innovators operating across MedTech, CleanTech, and AI-driven SaaS sectors, including Dos, Homebound, 4D Medicine Ltd, Furbnow, MNS, Myriad Wind Energy Systems, Healome Therapeutics, Neurosight, UNA Watch, and stack8s. The announcement highlights the fund's strategy of reinvesting in high-performing portfolio companies as they scale.LinknovateTop 10 Biomaterials Startups to Watch in 2025: Pioneering the Future of Materials Engineering -A curated list highlights ten startups pioneering sustainable biomaterials in 2025, including 4D Medicine, Cellbricks, and Tidal Vision, which are developing alternatives to plastics and leather through technologies like 3D bioprinting and cellular agriculture. Key developments include significant funding rounds for companies such as PACT and Tidal Vision, alongside strategic expansions and partnerships aimed at commercializing these bio-based solutions. These entities are reshaping industries ranging from healthcare to fashion by introducing regenerative, biodegradable, and climate-responsible materials.Tech.eu4D Medicine raises £3.4m for biomaterial platform4D Medicine raised £3.4m in a Series A round led by Oshen Holdings, with backing from DSW Ventures, SFC Capital, and others. The funds will complete pre-clinical testing of its first product range and seek FDA clearance for the US market. The company plans to raise a Series B early next year.BusinessCloud4D Medicine raises £3.4m to develop biomaterial for implants4D Medicine raised £3.4 million in Series A funding led by Oshen Holdings to develop its resorbable biomaterial 4Degra for 3D-printed implants. The funds will complete pre-clinical testing and seek FDA clearance for the US market, with total funding now at £5m. The company plans a Series B early next year.Uktechnews4D Medicine (t/a 4D Biomaterials) secures £3.4 Million Series A Investment led by Oshen Holdings4D Medicine raised £3.4m in a Series A led by Oshen Holdings, with backing from DSW Ventures, SFC Capital, and others. The funds will complete pre-clinical testing of its first product range and seek FDA clearance for the US market. The company plans to raise a Series B early next year.PharmiWeb.com4D Medicine raises £3.4m for unique biomaterial platform4D Medicine raised £3.4m in a Series A round led by Oshen Holdings, with backing from DSW Ventures and others. The funds will complete pre-clinical testing of its 4Degra biomaterial and seek FDA clearance for the US market. The company plans a Series B early next year.